MarketWatch  Aug 4  Comment 
Eli Lilly & Co. said early Friday that its migraine drug lasmiditan met its primary endpoint and a key secondary endpoint in a late-stage clinical trial. The company plans to submit for Food and Drug Administration approval in the second half of...
FiercePharma  Aug 1  Comment 
Analysts expected Eli Lilly’s Forteo to be the big challenge standing in the way of new Radius bone drug Tymlos. But Express Scripts apparently has other ideas. On Monday, the PBM giant said Forteo would get the boot from its 2018 national...
MedPage Today  Jul 31  Comment 
(MedPage Today) -- Olanzapine plus standard three-drug regimen
FiercePharma  Jul 26  Comment 
Eli Lilly’s rheumatoid arthritis med baricitinib was pegged as one of 2017’s hottest launches—and a threat to Pfizer’s rival drug Xeljanz. Well, cast aside those expectations. The Lilly drug won’t roll this year, and Xeljanz looks like...
Benzinga  Jul 26  Comment 
Despite a strong quarter, analysts see a difficult road ahead for Eli Lilly And Co (NYSE: LLY). “Even though Eli Lilly's launch execution has been outstanding," Leerink Managing Director Seamus Fernandez said, "the ways for LLY investors to...
FiercePharma  Jul 25  Comment 
Eli Lilly beat sales estimates in the second quarter, thanks to successful launches of drugs like Taltz to treat psoriasis. But the pressure is on to continue to innovate, so the company is revising its oncology strategy to boost its chances of...
FierceBiotech  Jul 25  Comment 
Eli Lilly is seeking partners for two-thirds of its midphase oncology compounds. The Big Pharma wants to offload six phase 2 candidates to focus its R&D dollars on a clutch of early to midstage assets it thinks can become the new standard of care.
MarketWatch  Jul 25  Comment 
Eli Lilly beats profit expectations, says NDA for RA treatment to be delayed

Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki